Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evalua...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2017-07, Vol.35 (19), p.2141-2148
Hauptverfasser:	Bardia, Aditya, Mayer, Ingrid A, Diamond, Jennifer R, Moroose, Rebecca L, Isakoff, Steven J, Starodub, Alexander N, Shah, Nikita C, O'Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M, Berlin, Jordan, Messersmith, Wells A, Ocean, Allyson J, Wegener, William A, Maliakal, Pius, Sharkey, Robert M, Govindan, Serengulam V, Goldenberg, David M, Vahdat, Linda T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antigens, Neoplasm - biosynthesis Antigens, Neoplasm - immunology Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Breast Cancer Breast Neoplasms, Male - drug therapy Breast Neoplasms, Male - immunology Breast Neoplasms, Male - metabolism Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cell Adhesion Molecules - biosynthesis Cell Adhesion Molecules - immunology Combined Modality Female Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Male Middle Aged Neoplasm Metastasis ORIGINAL REPORTS Phase I and Clinical Pharmacology Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - immunology Triple Negative Breast Neoplasms - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!